The Effects of Alendronate After Cure of Primary Hyperparathyroidism
Withdrawn before enrolling · Phase 4 · Has a placebo group
Conditions studied: Hyperparathyroidism
In brief
We are investigating whether, after surgical cure of primary hyperparathyroidism, alendronate provides even greater beneficial skeletal effects than parathyroidectomy alone. Primary Hyperparathyroidism (PHPT) is a disorder that can be associated with bone loss. After successful surgery for PHPT bone density improves without any treatment. However, it is possible that bone density might improve to an even greater extent if Fosamax is used after the surgical cure. Fosamax is approved by the FDA for the prevention and treatment of osteoporosis, and the goal of this project is to determine whether after successful surgical cure of PHPT, Fosamax is even better for the skeleton than just parathyroid surgery alone.
Key facts
- Study ID
- NCT00359385
- Run by
- Columbia University
- People needed
- 0
- Starts
- 2006-07-01
- Expected to finish
- 2009-09-01
- Last updated by the study team
- 2011-11-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- patients with PHPT who have a negative T-score by BMD at the lumbar spine before surgery;
- successful surgery for PHPT as documented by normalization of serum calcium and PTH levels within 1 week of study initiation.
You may not qualify if…
- vitamin D deficiency;
- any concomitant disease that might affect mineral metabolism such as hyperthyroidism, Paget's disease of bone, diabetes mellitus, chronic liver or renal disease, acromegaly, Cushing's syndrome, rheumatoid arthritis, myeloma;
- any woman who is within 5 years of the menopause;
- gastrointestinal disorders, surgery or drugs affecting absorption;
- treatment with a bisphosphonate within 2 years of parathyroidectomy;
- treatment with any of the following medications more recently than 6 months prior to enrollment: estrogens, progestins, raloxifene, calcitonin, systemic corticosteroids, fluoride, lithium, loop diuretics, methotrexate;
- abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia;
- inability to stand or sit upright for at least 30 minutes;
- increased risk of aspiration;
- hypersensitivity to alendronate;
- hypocalcemia;
- pregnancy or nursing; (women within childbearing years will be advised not to conceive during the study);
- age < 18 years old.
Where it is running
- CUMC — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.